Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis

Drug name

Zinbryta (daclizumab)

Company

Biogen and Abbive

Therapy class

IgG1 Monoclonal antibody

Current indication

Multiple sclerosis

Market sector

CNS

Development status

Approved in the US, Canada, Europe,
Expand
Close
Close
Close

Go Top